3000 patients join hunt for lung cancer biomarkers
NCT ID NCT06054854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is building a large collection of blood, urine, saliva, and other samples from 3000 people with lung nodules or lung cancer. Researchers hope to find biological markers that can help diagnose lung cancer earlier, predict how the disease will progress, and guide treatment choices. Participants provide extra samples during routine care, with no direct treatment involved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better diagnose lung cancer early and choose more effective treatments for each patient.
- What could go wrong
- This is an observational biobank study, not a treatment trial. It may take years to find useful biomarkers, and not all discoveries will lead to practical tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Larrey Hospital
RECRUITINGToulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Which lung biopsy method is safer and more accurate?
- Can a new PET tracer light up hidden cancers?